Mamoru Narukawa

Approval success rates of drug candidates based on target, action, modality, application, and their combinations

Shingo Yamaguchi, Masayuki Kaneko, Mamoru Narukawa · Clinical and Translational Science · 2021 · 96 citations · Full text

Substance Abuse, Drug Repositioning, Drug Candidates +15

Oral 5-aminolevulinic acid mediated photodynamic diagnosis using fluorescence cystoscopy for non-muscle-invasive bladder cancer: A randomized, double-blind, multicentre phase II/III study

Keiji Inoue, Satoshi Anai, Kiyohide Fujimoto et al. · Photodiagnosis and Photodynamic Therapy · 2015 · 76 citations

Urology, Genitourinary Cancer, Photodynamic Therapy +6

Significance of data mining in routine signal detection: Analysis based on the safety signals identified by the FDA

Chisato Fukazawa, Yasushi Hinomura, Masayuki Kaneko et al. · Pharmacoepidemiology and Drug Safety · 2018 · 50 citations

A Significant Anticancer Drug Approval Lag Between Japan and the United States Still Exists for Minor Cancers

Kenji Yamashita, Masayuki Kaneko, Mamoru Narukawa · Clinical Pharmacology & Therapeutics · 2018 · 29 citations

Drug Approval Lag, Cancer Management, Epidemiology Of Cancer +21

Points to consider: efficacy and safety evaluations in the clinical development of ultra-orphan drugs

Kojiro Maeda, Masayuki Kaneko, Mamoru Narukawa et al. · Orphanet Journal of Rare Diseases · 2017 · 28 citations · Full text